Thursday's Health Winners & Losers
Noven shares rose $1.24, or 9.2%, to $14.75.
Wednesday after close, Somaxon Pharmaceuticals (SOMX) reported a net loss of $5.7 million, or 31 cents a share, vs. $9.8 million, or 55 cents a share, for the year-ago quarter. Analysts were expecting a loss closer to 39 cents a share for the quarter, and JP Morgan upgraded the stock to neutral from underweight on Thursday. Shares garnered 89 cents, or 15.5%, to $6.65.
Less fortunate Thursday was Abraxis BioScience (ABBI), which reported adjusted third-quarter earnings of $23.1 million, or 15 cents a share, in the recent quarter, compared to $16.7 million, or 10 cents a share, in the year-ago period. And the company reported revenue of $241 million, vs. $203.1 million in the 2006 quarter, falling shy of estimates of analysts surveyed by Thomson Financial who expected 22 cents a share, on revenue of $253.9 million. Shares fell $2.29, or 9.5%, to $21.93.
Also, Corcept (CORT) gave up 49 cents, or 15.2%, to $2.75. The company reported a third-quarter loss of $3.4 million, or 9 cents a share, vs. a loss of $6.4 million, or 28 cents a share, in the year-ago period. The consensus target was for a loss of 9 cents a share.And hitting a new 52-week low, BioCryst (BCRX) aired its results as well. The company reported revenue of $20.5 million vs. $1.8 million in the year-ago quarter, and a net loss of $11 million, or 32 cents a share, compared to a loss of $15.6 million, or 53 cents a share, in the year-ago quarter. The consensus target was a loss of 28 cents a share on revenue of $10.51 million. Shares declined 72 cents, or 9.4%, to $6.95.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV